KITE 585

Drug Profile

KITE 585

Alternative Names: BCMA CAR T-cell therapy - Kite Pharma; KITE-585

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Developer Kite Pharma
  • Class Antineoplastics; CAR-T cell therapies; Immunoglobulin Fv fragments
  • Mechanism of Action Antigen receptor antagonists; Cell replacements; Gene transference; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 31 Oct 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03318861)
  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 08 Aug 2017 Kite Pharma files an IND application with the FDA in USA for Multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top